Janumet

Selected form

Method of action: Drugs Used In Diabets

Treatment option: Diabetic Ketoacidosis, Pancreatitis, Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Janumet

This foundational section defines the Sitagliptin/Metformin fixed-dose combination (known by the brand name Janumet), clarifying its identity, composition, and general purpose.

Property	Description
Active Ingredients	Sitagliptin Phosphate and Metformin Hydrochloride
Form	Oral tablet (film-coated, available in IR and XR formulations)
Pharmacological Class	Antihyperglycemic agent (Combination of a DPP-4 Inhibitor and a Biguanide)
General Purpose	Management of elevated blood sugar levels
Origin	Synthetic

What Type of Medicine is Janumet?

Janumet is a synthetic combination medicine designed to help manage elevated blood sugar levels in adults diagnosed with type 2 diabetes mellitus, classified as an antihyperglycemic agent. This medication is a fixed-dose combination product intended for oral administration, utilizing two distinct pharmacological approaches simultaneously. Using the two components together is clinically recognized for providing effective, sustained management when monotherapy is insufficient.

Composition and Physical Form of the Combination

The medicine contains two principal active ingredients: Sitagliptin Phosphate and Metformin Hydrochloride, which originate from two separate pharmacological classes. Sitagliptin belongs to the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, and Metformin is categorized as a Biguanide. Janumet is presented as a film-coated oral tablet, a solid dosage form designed for systemic absorption. This combination is indicated for use as an adjunct to diet and exercise. This prescription-only medication is often a convenient option for patients who require both agents for their management regimen, consolidating two medications into a single tablet.

The Overall Purpose of Dual Combination Therapy

The primary therapeutic purpose of Janumet is to establish and maintain sustained glycemic control for adult patients with type 2 diabetes mellitus. This dual combination therapy leverages the complementary actions of the DPP-4 Inhibitor and the Biguanide to target multiple physiological defects associated with the condition. By combining these two mechanisms, the medicine facilitates a more effective reduction in persistently elevated blood sugar levels, which constitutes the foundational goal of long-term diabetes management. This combination is particularly utilized when a patient’s blood sugar remains inadequately controlled on metformin monotherapy alone, serving as a key step-up in their treatment plan.

Regulatory References

What side effects are possible with Janumet ?

Possible Side Effects and Safety Information

The safety profile of Janumet (sitagliptin and metformin hydrochloride) is determined by the known risks of its two components, primarily focusing on metabolic, gastrointestinal, and hypersensitivity reactions.

Serious and Clinically Significant Adverse Reactions

Lactic Acidosis: This is a rare but severe metabolic complication, primarily associated with the metformin component, and can be fatal. Risk is significantly increased in patients with renal impairment, excessive alcohol intake, dehydration, or acute congestive heart failure.

Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported. If suspected, treatment must be discontinued immediately.

Hypersensitivity Reactions: Serious allergic reactions, including anaphylaxis, angioedema, Stevens-Johnson syndrome, and bullous pemphigoid, have been reported. These often occur within the first three months of treatment.

Other Warnings: Severe and disabling arthralgia (joint pain) has been reported with the sitagliptin class of medications. The drug is also associated with a decrease in Vitamin B12 levels. The risk of hypoglycemia is elevated when Janumet is combined with insulin or a sulfonylurea.

Common Adverse Reactions

The most commonly reported adverse reactions (5% incidence) in clinical trials include diarrhea, upper respiratory tract infection, and headache. Other common side effects are nausea, vomiting, and gas.

Restrictions and Monitoring

Janumet is contraindicated in patients with severe renal impairment, acute or chronic metabolic acidosis (including diabetic ketoacidosis), and a history of serious hypersensitivity to the components. Renal function must be assessed prior to treatment initiation and monitored regularly. The drug must be temporarily discontinued before or during iodinated contrast imaging procedures and elective surgery.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Janumet overdose primarily addresses the severe risk associated with its Metformin component: Lactic Acidosis. This condition is documented as a rare, but life-threatening medical emergency. Overdose may also lead to Hypoglycemia (low blood sugar).

Documented Manifestations and Urgent Actions

Overdose Presentation	Key Clinical Manifestation	Required Action
Lactic Acidosis	Non-specific symptoms: Malaise, Myalgias, Somnolence, Respiratory Distress, Abdominal Pain	Seek immediate medical attention/hospitalization
Hypoglycemia	Low blood sugar	Seek medical attention

In the event of a suspected overdose or symptoms of Lactic Acidosis, the official instruction is to stop taking Janumet immediately and call emergency services (e.g., 911) or a poison control center right away. The FDA and EMA classify Lactic Acidosis as a severe complication that necessitates urgent management. Treatment involves instituting general supportive measures in a hospital setting and administering prompt hemodialysis to clear the accumulated metformin from the blood. No specific antidote for a Janumet overdose is listed in official regulatory labeling. Increased risk of Lactic Acidosis is documented in patients with renal impairment, hepatic impairment, or who are age 65 or older.

Therapeutic Uses of Janumet

What Janumet Treats: Main Uses and Benefits

Janumet is used to help adults manage Type 2 Diabetes Mellitus by supporting better blood sugar control, which is its primary therapeutic purpose. The medicine is generally used when additional support is needed to manage blood sugar levels, often following initial treatments. Its application focuses on providing glycemic control in cases where blood sugar levels remain elevated despite other management efforts.

This medicine helps address symptoms related to high blood sugar, such as frequent urination and increased thirst. By assisting in the lowering of elevated glucose, it contributes to easing the overall symptom load associated with hyperglycemia. Janumet provides supportive relief during the long-term management of this chronic condition. This support contributes to improved comfort during periods of heightened symptoms and may assist in maintaining functional stability while managing the condition over time.

“This support helps patients cope more steadily with symptom fluctuations, assisting in the management of daily well-being.”

Quick Fact: Relief for High Blood Sugar Symptoms

Regulatory References

European Medicines Agency (EMA) product information

Eligibility and Restrictions for Use

Eligibility and Contraindications

Janumet is indicated for use exclusively in adults diagnosed with Type 2 Diabetes Mellitus. Its eligibility is determined primarily by physiological status and underlying health conditions, as mandated by regulatory documents.

Category	Status	Restriction Details
Approved Age Group	Allowed	Adults (18 years of age and older).
Type of Diabetes	Not Allowed	Must not be used for Type 1 Diabetes Mellitus or diabetic ketoacidosis.
Severe Renal Impairment	Contraindicated	Prohibited for patients with an estimated glomerular filtration rate (eGFR below 30 mL/min/1.73 m^2).
Moderate Renal Impairment	Not Recommended	For eGFR 30 to < 45 mL/min/1.73 m^2, the fixed combination is not recommended.
Hepatic Impairment	Contraindicated/Avoid	Use is prohibited (EMA) or advised to be avoided (FDA).
Pregnancy/Lactation	Restricted/Contraindicated	Contraindicated during breastfeeding. No adequate studies exist for pregnancy.
Hypersensitivity	Contraindicated	Prohibited for patients with a history of a serious allergic reaction to any component.

Use requires temporary discontinuation during procedures involving intravascular iodinated contrast or before certain surgeries.

What should I know about interactions with other medicines?

Janumet Interactions with other medicines and products

The official regulatory profile for Janumet (Sitagliptin/Metformin) documents specific interaction patterns that affect the systemic exposure and pharmacodynamic action of its components. The structure of these interactions is primarily focused on Metformin's renal clearance and additive glucose effects.

Interaction Type	Interacting Substance/Class	Regulatory Outcome
Contraindication/Restriction	Iodinated contrast agents	Formal restriction requires temporary discontinuation at the time of or before the procedure due to the heightened risk of lactic acidosis
Transporter-Mediated PK	Cimetidine, Dolutegravir, Ranolazine	These medicines increase Metformin plasma concentrations by competing for the renal tubular transporters OCT2 and MATE
Pharmacodynamic	Insulin/Sulfonylureas	Results in an additive hypoglycemic effect, increasing the risk of low blood sugar
Pharmacodynamic	Hyperglycemic Agents (e.g., corticosteroids)	May reduce the drug’s glucose-lowering effectiveness
Other PK	Cyclosporine	Increases Sitagliptin plasma concentration due to P-glycoprotein inhibition

Substance-Specific Interaction Notes

Alcohol: Consumption, especially excessive acute or chronic intake, is officially associated with an increased risk of lactic acidosis when using the Metformin component.
Food: Co-administration with food decreases the rate and extent of Metformin absorption.
CYP Enzymes: Sitagliptin is a documented weak inhibitor of CYP2C8, which may increase the exposure of co-administered medicines predominantly cleared by this enzyme.

Mechanism of Action

Sitagliptin: Incretin Hormone System Modulation

The sitagliptin component functions as a selective inhibitor of the enzyme Dipeptidyl Peptidase-4 (DPP-4). This enzyme is responsible for the inactivation of incretin hormones (GLP-1 and GIP). By blocking DPP-4, the half-life of active incretins is prolonged, which leads to an increased, glucose-dependent release of insulin from pancreatic beta-cells and a coordinated suppression of glucagon secretion from alpha-cells.

Metformin: Modulation of Hepatic Glucose Production

The metformin component acts primarily by altering the cellular energy state, mainly within liver cells, through the inhibition of the mitochondrial respiratory chain. This molecular event indirectly leads to the activation of the metabolic sensor AMPK. The AMPK activation cascade subsequently suppresses the expression of key enzymes involved in gluconeogenesis, thereby decreasing hepatic production and release of glucose into the bloodstream.

Dual-Component Mechanistic Synergy

The combination product leverages these two distinct mechanisms simultaneously. Sitagliptin modulates the hormonal response of the pancreas, while Metformin acts on peripheral insulin signaling and hepatic glucose output, resulting in a coordinated, multi-level action that influences glucose homeostasis.

Dosage and Administration Information

How to Use Janumet

Janumet (sitagliptin/metformin) is strictly intended for oral administration as a film-coated tablet, used as part of a long-term plan to improve glycemic control in adults with type 2 diabetes. The medicine is classified into two main formulations: immediate-release (IR) and extended-release (XR), each with a specific frequency requirement.

Dosing and Frequency Guidelines

The total daily dosage must not exceed 100 mg of sitagliptin and 2000 mg of metformin HCl. The dosage is individualized, often starting with lower doses of the metformin component for those not previously treated with it. Gradual dose increases are typically recommended to enhance gastrointestinal tolerance.

Formulation Type	Dosing Frequency	Administration Timing
Immediate-Release (IR)	Twice Daily (BID)	Taken with meals
Extended-Release (XR)	Once Daily (QD)	Taken with a meal, preferably the evening meal

Administration Requirements

Tablet Integrity: The immediate-release tablets should not be split or divided. The extended-release (XR) tablets must be swallowed whole and must not be crushed, split, or chewed, as this alters the intended drug release.

Population Restrictions: The fixed-dose combination is not recommended for initiation in patients with an estimated Glomerular Filtration Rate (eGFR between 30 and <45 mL/min/1.73 m²). Furthermore, it is contraindicated in patients with an eGFR below 30 mL/min/1.73 m². Use in children and adolescents under 18 years of age is not recommended. If a dose is missed, it should be taken as soon as remembered unless it is near the time for the next dose; a double dose should not be taken.

Procedural Constraints: The medication is generally required to be temporarily discontinued prior to or at the time of undergoing iodinated contrast imaging procedures.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Janumet

The evaluation of Janumet (Sitagliptin/Metformin) is supported by clinical trials, including Randomized Controlled Trials (RCTs). These trials are designed to explore patterns related to blood sugar control by comparing treatment groups to placebo or to the individual components of the drug. The primary measurement examined in this research is the blood sugar marker, Glycosylated Hemoglobin ( HbA1c).

Evidence for Use as Initial Dual Therapy

The research exploring the use of the Janumet combination as a starting treatment focused on adult patients whose Type 2 Diabetes involved inadequate glycemic control with diet and exercise alone. Studies were conducted as short-term RCTs. The research examined changes in measured HbA1c and in Fasting Plasma Glucose, tracking the proportion of participants who reached a specific blood sugar target. Data regarding the long-term continuation of the measured glycemic patterns beyond the core efficacy trials are limited.

Evidence for Use as Step-Up Therapy

Studies also explored scenarios involving the addition of the sitagliptin component to patients already taking metformin who had inadequate blood sugar control. These controlled add-on trials monitored blood sugar marker shifts and how HbA1c evolved in the observed populations, typically over six months. Evidence for this indication primarily focused on short-term glycemic changes, and long-term effects over many years are not fully established.

Key Research Gaps and Uncertainties

Research has focused on exploring short-term changes in blood sugar markers, but several key areas remain uncertain. Clinical studies were not designed to confirm a reduction in heart attacks or strokes, meaning evidence is limited for macrovascular outcomes. Data for certain groups remain insufficient, specifically for patients with a history of pancreatitis, who were typically excluded from the main clinical trials. Furthermore, the effectiveness and safety of the medication have not been established in the pediatric population (children and adolescents under 18 years).

Key Studies & References Sitagliptin and Metformin: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Janumet (FAQ)

Q: Is Janumet safe to take during pregnancy or while breastfeeding?

Official regulatory documents indicate that Janumet is generally not recommended for use during pregnancy, as adequate studies have not been conducted in pregnant women. The medication is listed as contraindicated while breastfeeding.

Q: How long does it take for Janumet to start lowering blood sugar?

Regulatory documents primarily focus on the long-term effectiveness of the medication. Clinical trials tracking the blood sugar marker HbA1c (Glycosylated Hemoglobin) generally assess changes in patients over a period of 24 weeks or more to determine sustained glucose control.

Q: Can Janumet cause weight loss or weight gain?

Based on data from clinical trials, the combination product is generally associated with weight-neutral effects or, for some patients, a small degree of weight loss. Changes in body weight are an observation monitored during clinical trial experience.

Q: What do the different Janumet tablet colors and markings mean?

Official regulatory documents and prescribing information list the specific physical characteristics of the tablets. This includes the tablets' shape, color, and imprinting, which are specific to the dosage strength (milligram amount) of the medication.

Q: How should I safely dispose of expired Janumet?

Official guidelines outline specific steps for disposal, which generally recommend utilizing a drug take-back program or mail-back service. If a take-back option is unavailable, the guidelines state the medicine should be mixed with an undesirable substance before being discarded. Flushing the medication is generally not recommended.

Q: Can Janumet be split, crushed, or chewed?

Administration requirements are outlined in the official product information. The immediate-release (IR) tablets should not be split or divided. The extended-release (XR) tablets must be swallowed whole and should not be crushed, split, or chewed, as this alters the intended drug release.

Q: What should I do if I miss a dose of Janumet?

The official guidance for a missed dose states that it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is to be skipped. The guidance also specifies that a double dose should not be taken to compensate for a missed dose.

Q: Is Janumet an insulin or an oral tablet?

Janumet is an oral film-coated tablet and is not a form of insulin. It is classified as an antihyperglycemic agent—a combination medicine that helps manage high blood sugar levels in adults with type 2 diabetes.

How should Janumet be stored and disposed of?

How to Store and Dispose of Janumet?

This section outlines the official, label-based storage and disposal requirements for Janumet tablets, strictly following government regulatory guidelines.

Official Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F).
Container Rule	Keep the medicine in its original container with the cap tightly closed to protect it from heat, light, and moisture.
Access Prevention	Keep Janumet out of the sight and reach of children and pets in a safe, dry location.

Disposal Instructions

To discard unused or expired tablets safely, the official recommendation is to utilize a drug take-back program or mail-back service. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a plastic bag or container, and placed in the household trash. Do not flush Janumet down the toilet or throw it into wastewater unless specifically advised.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.